Drugs / GSK2434735
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01563042 | Feb → May 2012 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2434735 | “GSK2434735 is a bispecific antibody to IL-13 and IL-4.” NCT01563042 ↗ |
| Route | Intravenous | “GSK2434735 administered as a single intervenous dose at the beginning of the study” NCT01563042 ↗ |